DAX®15.669,29+1,00%TecDAX®3.668,39+0,54%Dow Jones 3035.061,55+0,68%Nasdaq 10015.111,79+1,15%
finanztreff.de

DGAP-Adhoc: Heidelberg Pharma AG Raises EUR 20 Million From Private Placement

| Quelle: Dow Jones Newsw... | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen

DGAP-Ad-hoc: Heidelberg Pharma AG / Key word(s): Financing
Heidelberg Pharma AG Raises EUR 20 Million From Private Placement
15-Jun-2021 / 22:16 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA
OR JAPAN.
Ad hoc announcement - Inside information pursuant to Article 17 MAR
Heidelberg Pharma AG Raises EUR 20 Million From Private Placement
Ladenburg, Germany, 15 June 2021 - Heidelberg Pharma AG (FSE: HPHA) announced that it has successfully raised
approximately EUR 20 million in gross proceeds through a private placement via an accelerated book building
transaction. Heidelberg Pharma issued 3,106,637 new shares from authorized capital, which corresponds to approximately
10% of the current share capital. The price per share was EUR 6.44, which represents a discount of approximately 3.9%
to the daily closing price.
The new shares were allocated to new biotech specialist institutional investors, including Polar Capital Biotech
Investment Fund and Invus, amongst others, and 1,943,565 shares were allocated to DH-LT-Investments GmbH, St. Leon-Rot,
Germany, an investment company of Mr. Dietmar Hopp. The capital measure will increase the total number of registered
shares after the issuance to 34,173,009.
The issuance of new shares was resolved today by the Executive Management Board and Supervisory Board of Heidelberg
Pharma AG. The new shares will be admitted to trading on the Frankfurt Stock Exchange after the capital increase has
been entered in the commercial register.
The capital increase has been executed by Bryan, Garnier & Co, acting as Sole Global Coordinator and Sole Bookrunner.
+++ End of the ad hoc announcement +++
Information and Explanation of the Issuer to this News:
Important notes
This communication does not constitute or form part of an offer of securities for sale or solicitation of an offer to
purchase securities in the United States, Canada, Australia, Japan or in any other jurisdiction in which such offer may
be restricted. The securities referred to in this communication have not been, and will not be, registered under the US
Securities Act of 1933, as amended (the 'Securities Act'), and may not be offered or sold in the United States, except
on the basis of an applicable exemption from registration or in a transaction not subject to registration under the
Securities Act. There will be no public offering of securities in the United States or anywhere else.
In the United Kingdom, this communication is directed only at persons who: (i) are qualified investors within the
meaning of the Financial Services and Markets Act 2000 (as amended) and any relevant implementing measures and/or (ii)
are outside the United Kingdom or (iii) have professional experience in matters relating to investments and fall within
the definition of 'investment professionals' contained in article 19 (5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (as amended) (the 'Order') or are persons falling within article 49 (2)(a) to (d)
(high net worth companies, unincorporated associations, etc.) of the Order, or fall within another exemption to the
Order (all such persons referred to in (i) to (iii) above together being referred to as 'Relevant Persons'). Any person
who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or
investment activity to which this communication relates is available only to Relevant Persons and will be engaged in
only with Relevant Persons.
About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology
specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology
platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party
collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma and will enter clinical
development shortly. HDP-102, a CD37 ATAC for Non-Hodgkin's lymphoma and HDP-103, a PSMA ATAC for metastatic
castration-resistant prostate cancer, are in preclinical testing.
Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More
information is available at www.heidelberg-pharma.com.
Contact IR/PR support
Heidelberg Pharma AG MC Services AG
Sylvia Wimmer Katja Arnold (CIRO)
Tel.: +49 89 41313829 Managing Director & Partner
Email: investors@hdpharma.com Tel.: +49 89 21022840
Gregor-Mendel-Str. 22, 68526 Ladenburg Email: katja.arnold@mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will' 'should' 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

15-Jun-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


Language: English
Company: Heidelberg Pharma AG
Gregor-Mendel-Str. 22
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: investors@hdpharma.com
Internet: www.heidelberg-pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf,
Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1208373

End of Announcement DGAP News Service

1208373 15-Jun-2021 CET/CEST



Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1208373&application_name=news


(END) Dow Jones Newswires

June 15, 2021 16:18 ET ( 20:18 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:

Aktuelle Videos

HSBC Trading TV

Werbung

Trading-Tipp

Börsen & Märkte

US-Marktüberblick

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 30 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen